Icosavax, Inc.

Icosavax, Inc. (ICVX) priced its initial public offering on Jul 30, 2021 at $15.00 per share, within its $14.00–$16.00 range, raising $182M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $562.6M. Jefferies was lead-left underwriter, joined by TD Cowen, Evercore ISI and William Blair. Latham & Watkins advised the company and WilmerHale advised the underwriters.

Icosavax, Inc. is a biopharmaceutical company using a virus-like particle platform to develop vaccines against infectious diseases, starting with serious respiratory diseases. Its candidates target viral causes of pneumonia and are being developed for older adults.

Status

IPO

Ticker

ICVX

Exchange

Nasdaq Global Select

Priced

Jul 30, 2021

IPO price

$15.00

Price range

$14.00–$16.00

Raised

$182M

Market cap at IPO price

$562.6M

First filed

Jul 7, 2021

Underwriters

Jefferies, TD Cowen, Evercore ISI and William Blair

Company counsel

Latham & Watkins

Underwriters' counsel

WilmerHale

Sector

Biotech & pharma

Country / state

WA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.